...
首页> 外文期刊>Biomaterials >Multistage pH-responsive mucoadhesive nanocarriers prepared by aerosol flow reactor technology: A controlled dual protein-drug delivery system
【24h】

Multistage pH-responsive mucoadhesive nanocarriers prepared by aerosol flow reactor technology: A controlled dual protein-drug delivery system

机译:气溶胶流量反应器技术制备多级PH响应粘膜粘膜纳米载体:受控双蛋白 - 药物输送系统

获取原文
获取原文并翻译 | 示例

摘要

Nanotechnology based drug delivery systems are anticipated to overcome the persistent challenges in oral protein and peptide administration, and lead to the development of long awaited non-invasive therapies. Herein, an advanced single-step aerosol flow reactor based technology was used to develop a multifunctional site specific dual protein-drug delivery nanosystem. For this purpose, mucoadhesive porous silicon (PSi) nanoparticles encapsulated into a pH-responsive polymeric nanomatrix was developed for advanced oral type 2 diabetes mellitus therapy with an antidiabetic peptide, glucagon like peptide-1 (GLP-1), and the enzyme inhibitor, dipeptidyl peptidase-4 (DPP4). Chitosan surface modification inherited the mucoadhesiveness to the nanosystem which led to enhanced cellular interactions and increased cellular compatibility. An advanced aerosol flow reactor technology was used to encapsulate the chitosan modified nanoparticles into an enteric polymeric nanomatrix. The pH-sensitive polymeric matrix simultaneously prevented the gastric degradation of the encapsulated peptide and also preserved the mucoadhesive functionality of the chitosan-modified PSi nanoparticles in the harsh stomach environment. The multidrug loaded nanosystem showed augmented intestinal permeability of GLP-1, evaluated in an in vitro cell-based intestinal epithelium model, attributed to the permeation enhancer effect of chitosan and inhibition of GLP-1 degradation by the DPP4 inhibitor. The applied technology resulted in the development of a dual-drug delivery nanosystem that synergizes the antidiabetic effect of the loaded peptide and the enzyme inhibitor, thereby indicating high clinical potential of the system and preparation technique. (C) 2015 Elsevier Ltd. All rights reserved.
机译:基于纳米技术的药物递送系统预计将克服口腔蛋白和肽给药中的持续挑战,并导致长期等待的非侵入性疗法的发展。在此,用于开发基于先进的单步气流流动反应器的技术来开发多功能位点特异性双蛋白 - 药物递送纳米系统。为此目的,将粘膜粘附多孔硅(PSI)纳米颗粒包封成pH-响应聚合物纳米腹覆盖物,用于高级口服2型糖尿病Mellitus疗法,用抗糖尿病肽,肽-1(GLP-1)和酶抑制剂,二肽肽肽酶-4(DPP4)。壳聚糖表面改性继承了纳米系统的粘膜粘附性,其导致细胞相互作用增加和细胞兼容性增加。使用先进的气溶胶流量反应器技术将壳聚糖改性的纳米颗粒包封成肠溶聚合物纳米瘤。 pH敏感的聚合物基质同时防止包封肽的胃部降解,并保留了壳聚糖改性的PSI纳米颗粒在苛刻的胃环境中的粘膜粘附功能。多药物纳米系统显示出GLP-1的增强肠道渗透性,在体外细胞基肠上皮模型中评估,归因于壳聚糖的渗透增强剂和抑制DPP4抑制剂的GLP-1降解。所应用的技术导致双药物递送纳米系统的开发,该纳米系统协同增长肽肽和酶抑制剂的抗糖尿病作用,从而表明系统的高临床电位和制备技术。 (c)2015 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号